More than 82 million people could be living with dementia by 2030,1 the majority in low-income and middle-income countries where access to specialist care and diagnostic tests is highly variable.

Discover the latest non-invasive Alzheimer’s detection breakthroughs, from AI and heart rate tracking to digital twins and sensor tests.

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

It promises the benefits of a 10,000-step walk in just 30 minutes. No gym membership required. Just a pair of shoes and a ...

New drugs show promise, and research finds value in vaccines, antivirals, exercise and probiotics.

One-third of people older than 85 in the United States are estimated to live with Alzheimer's disease today, according to the ...

A few limited clinical trials of lithium for Alzheimer’s disease have shown some efficacy, but the lithium compounds they ...

This research offers hope. By finding brain diseases earlier, we might be able to slow them down or manage them better. If ...

TOKYO (AP) — Japan’s meteorological agency issued a tsunami alert for Japan’s Pacific coast, upgrading an earlier advisory stemming from the powerful, magnitude 8.0 quake that hit on ...

Japanese electronics and technology giant Panasonic has chosen a new chief at one of its companies after eking out a 1.2% rise in its first quarter profit.

Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.